Elanco Animal Health (ELAN) Net Equity Issued and Repurchased (2020 - 2021)
Elanco Animal Health (ELAN) reported Net Equity Issued and Repurchased of $500.0 million for Q4 2021, down 59.02% sequentially from $1.2 billion in Q1 2020.
Elanco Animal Health (ELAN) Net Equity Issued and Repurchased (2020 - 2021) Analysis & Trends
Elanco Animal Health (ELAN) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $500.0 million in Q4 2021.
- For the quarter ending Q4 2021, Net Equity Issued and Repurchased changed N/A year-over-year to $500.0 million; the trailing twelve-month figure through Dec 2021 stood at $500.0 million (down 59.02% YoY), and the FY2022 full-year result was $425.0 million, down 15.0% from the prior year.
- Net Equity Issued and Repurchased retreated to $500.0 million in Q4 2021, from $1.2 billion in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $1.2 billion in Q1 2020 to a low of $500.0 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 500,000.00 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 500.00 Mn |
| Dec 31, 2021 | 500.00 Mn |
| Mar 31, 2020 | 1.22 Bn |
| Mar 31, 2020 | 1.22 Bn |